Dr Marc Moore
1 - 2 out of 2Page size: 100
- 2022
- Forthcoming
Targeted exon skipping of NF1 exon 17 as a Therapeutic for Neurofibromatosis Type I
Leier, A., Moore, M., Liu, H., Daniel, M., Hyde, A. M., Messiaen, L., Korf, B. R., Selvakumaran, J., Ciszewski, L., Lambert, L., Foote, J., Wallace, M. R., Kesterson, R. A., Dickson, G., Popplewell, L. & Wallis, D., 15 Mar 2022, (Accepted/In press) In: Molecular therapy. Nucleic acids.Research output: Contribution to journal › Article › peer-review
- 2021
- Published
Restoration of Normal NF1 Function with Antisense Morpholino Treatment of Recurrent Pathogenic Patient-Specific Variant c.1466A>G; p.Y489C
Awad, E., Moore, M., Liu, H., Ciszewski, L., Lambert, L., Korf, B. R., Popplewell, L., Kesterson, R. & Wallis, D., 7 Dec 2021, In: Journal of Personalized Medicine. 11, 12, 1320.Research output: Contribution to journal › Article › peer-review